Lyra Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lyra Therapeutics Inc (LYRA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lyra Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 1,981M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-93.0% annualized vs trailing 12 months), vs accelerating (+78.9%) for its tracked peer group.
- Growth: Lyra Therapeutics Inc generated -96.7% revenue growth year over year in Q4 2025, vs 10.9% for its tracked competitors combined.
- Profitability: Its -99,300.0% net margin compares with -2.6% for the peer group.
- Peer revenue share: Lyra Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.58M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LYRA Sales vs. its Competitors, Q4 2025
Lyra Therapeutics Inc reported revenue contraction of 96.65 % year on year in Q4 2025, below its competitors' combined revenue growth of 10.87 %.
With a net margin of -99,300.00 %, Lyra Therapeutics Inc reported lower profitability than its competitors (-2.63 %).
Lyra Therapeutics Inc generated 0.00 % of the combined sales of its peer group, down from 0.03 % a year earlier.
Lyra Therapeutics Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Lyra Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lyra Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lyra Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lyra Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs -96.7% for Lyra Therapeutics Inc. Lyra Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Lyra Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lyra Therapeutics Inc | - | No | No | Yes |
| Competitors combined (16) | ||||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LYRA Stock Performance relative to its Competitors
LYRA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Avita Medical Inc | 282.9% | Outperformed |
| 2 | Pulse Biosciences Inc | 282.9% | Outperformed |
| 3 | Aclaris Therapeutics Inc | 282.9% | Outperformed |
| 4 | Establishment Labs Holdings Inc | 282.9% | Outperformed |
| 5 | Ascendis Pharma A | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lyra Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lyra Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Lyra Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lyra Therapeutics Inc | 0.30 | 0.40 |
| Ascendis Pharma A | 14,351.46 | 814.20 |
| Pulse Biosciences Inc | 3,562.42 | 1.19 |
| Establishment Labs Holdings Inc | 1,877.18 | 245.11 |
| Inmode Ltd | 924.73 | 370.50 |
| Mimedx Group Inc | 617.05 | 354.09 |
| SUBTOTAL | 22,943.18 | 2,269.12 |
Sign in to see all competitors of Lyra Therapeutics Inc .
Sources: Lyra Therapeutics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lyra Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lyra Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Lyra Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Photrexa | Company report | 85% |
| AvoneX | Company report | 85% |
| Vivitrol | Company report | 85% |
| Risperdal | Company report | 85% |
| Linzess | Company report | 85% |
| XenMatrix | Company report | 85% |
| Taxus | Company report | 85% |
| Optinose Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Lyra Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Lyra Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Lyra Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Aclaris Therapeutics Inc | Single reportable segment 100.00 % |
| Apyx Medical Corp | Surgical Aesthetics 90.01 % |
| Femasys Inc | Single Reportable Segment 100.00 % |
| Nuo Therapeutics Inc | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Lyra Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lyra Therapeutics Inc | 0 | 14,741 | -1,071,074 |
| Ascendis Pharma A | 14,351 | 8,141,968 | -2,578,202 |
| Pulse Biosciences Inc | 3,562 | 10,216 | -690,138 |
| Establishment Labs Holdings Inc | 1,877 | 244,128 | -38,736 |
| Inmode Ltd | 925 | 7,561,122 | 1,914,918 |
| Mimedx Group Inc | 617 | 438,225 | 7,719 |
| PEERS TOTAL | 22,943 | 584,422 | -212,902 |
Sign in to see all peers for Lyra Therapeutics Inc .
Lyra Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Establishment Labs Holdings Inc | Non-US 63.44 % |
| Inmode Ltd | US 53.62 % |
| Avita Medical Inc | US 96.46 % |
| Sensus Healthcare Inc | US 78.17 % |
| Femasys Inc | US 97.83 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Lyra Therapeutics Inc .
Lyra Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 220 companies in Lyra Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Lyra Therapeutics Inc ranks #0 of 220 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 597, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 151,974 | 13.32 % |
| 2 | Medtronic Plc | 122,252 | 10.71 % |
| 3 | Stryker Corp | 116,723 | 10.23 % |
| 4 | 3m Company | 88,262 | 7.73 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Resmed Inc | 1,234 | 5.2% |
| 9 | Alcon inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 0 | Lyra Therapeutics Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Lyra Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-20.
Lyra Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (331 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 49.59 % (avg) | -49.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.61 % (avg) | - |
| Capital Intensity (Capex / Revenue) | - | 7.55 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lyra Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (331 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 35.6x | - |
| EV / EBITDA | - | 17.7x | - |
| P/B | -3.2x | 4.5x | -7.8x |
| Return on Equity | 1,211.14 % | industry aggregate | 1,202.72 % |
| Return on Invested Capital | -92.42 % | -3.24 % (avg) | -89.18 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lyra Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 14.31 % | -1.54 % | -74.05 % |
| Operating Margin | - | - | -4,131.03 % | - | - | - |
| Return on Invested Capital | -22.30 % | -38.96 % | -34.67 % | -35.61 % | -84.46 % | -92.42 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lyra Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 597 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Lyra Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Lyra Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Lyra Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 1,202.7 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-93.0% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lyra Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lyra Therapeutics Inc | 2.39 | 2.50 | - |
| Ascendis Pharma A | 0.58 | 1.04 | - |
| Pulse Biosciences Inc | 9.01 | 9.31 | - |
| Establishment Labs Holdings Inc | 0.95 | 3.26 | 13.16 |
| Inmode Ltd | 4.28 | 9.88 | - |
| Mimedx Group Inc | 2.95 | 4.77 | 0.07 |
Sign in to see all peers for Lyra Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lyra Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lyra Therapeutics Inc | Q4 2025 | -96.7 % | - |
| Ascendis Pharma A | Q4 2025 | +106.9 % | - |
| Pulse Biosciences Inc | Q2 2026 | - | - |
| Establishment Labs Holdings Inc | Q2 2026 | +31.7 % | - |
| Inmode Ltd | Q4 2025 | -6.2 % | -48.2 % |
| Mimedx Group Inc | Q2 2026 | -34.3 % | - |
| PEERS TOTAL | +32.7 % | - |
Sign in to see all peers for Lyra Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lyra Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lyra Therapeutics Inc | Q4 2025 | - | - |
| Ascendis Pharma A | Q4 2025 | +124.1 % | - |
| Pulse Biosciences Inc | Q2 2026 | - | -26.8 % |
| Establishment Labs Holdings Inc | Q2 2026 | +23.9 % | +76.2 % |
| Inmode Ltd | Q4 2025 | +2.3 % | +45.3 % |
| Mimedx Group Inc | Q2 2026 | +11.0 % | +234.1 % |
Sign in to see all peers for Lyra Therapeutics Inc .
Lyra Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lyra Therapeutics Inc | - | - | - |
| Ascendis Pharma A | - | - | - |
| Pulse Biosciences Inc | - | - | - |
| Establishment Labs Holdings Inc | - | - | - |
| Inmode Ltd | 12.24% | 13.49% | 13.73% |
| Mimedx Group Inc | 1.99% | 2.38% | 2.61% |
Sign in to see all peers for Lyra Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lyra Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lyra Therapeutics Inc | - | 0.74 |
| Ascendis Pharma A | - | 17.63 |
| Pulse Biosciences Inc | - | 3,006.26 |
| Establishment Labs Holdings Inc | - | 7.66 |
| Inmode Ltd | 9.88 | 2.50 |
| Mimedx Group Inc | 103.76 | 1.74 |
| PEERS AVERAGE | - | 10.11 |
Sign in to see all peers for Lyra Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.